The retrospective analysis included eight triple-class refractory RRMM patients who had received a median of 3.5 prior lines of therapy. Notably, several patients presented with high-risk features, including extramedullary disease. Despite this, treatment with Pepaxti in combination with dexamethasone showed an overall response rate (ORR) of 37.5%, with partial responses seen even among patients with advanced disease manifestations.

”Our experience adds to the growing body of real-world evidence on melflufen in relapsed and refractory myeloma. Even in a high-risk patient cohort, we observed encouraging disease control with a manageable safety profile,” says Dr. Etta Conticello, Division of Hematology, Azienda Policlinico-S. Marco, University of Catania.

“These real-world findings provide further support for Pepaxti’s potential benefit in heavily pretreated patients with limited treatment options, including those with aggressive disease phenotypes,” says Stefan Norin, Chief Medical Officer at Oncopeptides. “Importantly, the outcomes align with the results of our HORIZON trial, reinforcing the clinical value of Pepaxti across both trial and real-life settings.”

The data underline Pepaxti’s role as a viable treatment option for patients with advanced RRMM for patients who have received at least three prior lines of therapy and whose disease has progressed on or after the last therapy.
“It is truly encouraging to see how real-world clinical experience continues to confirm the potential of Pepaxti in treating patients with advanced multiple myeloma. Close collaboration with the medical community is essential as we work to address the significant unmet needs of patients with limited treatment options,” says Bruno Bolognese, Head of European Medical Affairs at Oncopeptides.

For more information, please visit oncopeptides.com. You can also find the abstract in the Abstract Book from the European Myeloma Network Meeting.